CERo Therapeutics Holdings, Inc. presented interim Phase 1 data for its lead T‑cell therapy, CER‑1236, at the ASTCT/CIBMTR Tandem Meeting in Salt Lake City on February 4, 2026. The oral poster reported that the first four treated patients experienced no dose‑limiting toxicities or cytokine release syndrome, and that the engineered cells expanded 20‑ to 70‑fold in vivo, peaking between days 7 and 14. An index patient who progressed from myelodysplastic syndrome to acute myeloid leukemia received four infusions over five months and achieved platelet transfusion independence for more than two months, exceeding the 56‑day durability benchmark used in the field.
The safety profile and robust expansion support CERo’s claim that its proprietary CER‑T platform can harness both adaptive and innate immune mechanisms, potentially widening the therapeutic window beyond current CAR‑T therapies. The data also reinforce the company’s Fast Track and Orphan Drug designations for AML, positioning CER‑1236 for accelerated regulatory review if subsequent trials confirm efficacy.
CERo is an early‑stage biotechnology company that trades on the OTCQB market and has a very low market capitalization. The company has historically relied on financing rounds to fund its pipeline and has reported operating losses in prior periods. The presentation of positive safety data is therefore a key milestone that may help secure additional capital and strengthen investor confidence in the company’s long‑term strategy.
Chief Medical Officer Robert Sikorski noted that the early clinical findings “support continued evaluation of CER‑1236 and validate the platform’s dual‑mechanism approach.” He added that the durability observed in the index patient is encouraging for the company’s plans to expand the therapy into broader AML indications. The company’s leadership has emphasized that the next steps will involve enrolling additional patients in the ongoing Phase 1/1b study and preparing for a pivotal Phase 2 trial.
The data were well received by the scientific community, with several analysts noting the significance of a safety‑first profile in a disease area with limited treatment options. While the company’s stock remains thinly traded, the presentation is expected to attract attention from investors seeking early‑stage opportunities in the AML space and may prompt additional funding rounds or strategic partnerships to support the therapy’s development.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.